Introduction
A deep tech spinout’s FTO is not the same analysis as a software startup’s FTO or a consumer technology company’s FTO. The standard startup FTO covers third-party patents that might block the product. A deep tech spinout FTO covers that — and two additional IP layers that are unique to companies that originate from university or public research institution R&D programmes: background IP retained by the founding institution, and third-party tool licences that were embedded in the research workflow under research-only terms that do not automatically extend to commercial use.
Missing either of the additional layers produces a commercially dangerous gap. A spinout that reaches its first commercial deal — whether a licence agreement, an enterprise customer contract, or an acquisition — with an incomplete FTO may be representing that its technology is free to commercialise when it is not. The university retains rights it has not licensed to the spinout. Or a third-party software tool used throughout the development phase is licensed for research only, and the commercial use of products developed using that tool may require a separate commercial licence that has not been obtained.
Our guide on FTO for startups covering what early-stage companies need to clear before their first commercial deal covers the standard startup FTO framework. This article covers the three additional dimensions that make deep tech spinout FTO structurally different — and what the first commercial deal actually requires to be IP-clean.
Why Deep Tech Spinout FTO Is Structurally Different
The three-layer IP complexity unique to spinouts: A conventional startup builds its technology from scratch — or licenses specific third-party components under commercial terms from the outset. A deep tech spinout commercialises technology developed in a university research context, which means it inherits three IP layers that a conventional startup does not have to navigate. Background IP: the pre-existing and concurrently developed IP owned by the university that the spinout’s technology depends on or incorporates. Third-party research licences: the licences to tools, datasets, materials, and software that were obtained for research purposes and may not cover commercial use. The external patent landscape: the third-party patents that cover the technology space, which were assessed for novelty and inventive step during the research phase but were never assessed for FTO clearance because the research context did not require it.
Why the university IP relationship creates unique FTO complexity: The spinout’s relationship with its founding university is governed by a spinout agreement or IP assignment agreement that specifies what IP has been transferred to the spinout, what has been retained by the university, and what the spinout is licensed to use. This agreement is the foundation document for the spinout FTO — because it defines what the spinout actually owns or has the right to use. A spinout that has not reviewed this agreement carefully before its first commercial deal may be commercialising technology that includes elements it has not been licensed to commercialise, or may be warranting that it owns IP that the university actually retains.
The timeline pressure: Deep tech spinouts frequently face commercial deal timelines that are compressed relative to the complexity of their IP position. An industrial partner interested in an exclusive licence or a technology acquisition will apply commercial pressure to close quickly. The three-layer FTO that a deep tech spinout requires takes longer to complete than a standard startup FTO — because the background IP audit, the research licence review, and the external patent landscape search each require systematic effort that cannot be compressed without creating analytical gaps. Managing this timeline pressure without cutting corners requires planning the FTO well in advance of the anticipated commercial deal timeline.
Layer One: Background IP Owned by the Founding University
What background IP is: Background IP is the intellectual property created before or independently of the specific research programme that led to the spinout. Universities typically retain ownership of background IP — including patents, know-how, and copyright in research software and datasets — that was created using university resources, by university employees, or under research grants administered by the university. The spinout may have been granted a licence to use this background IP for the purpose of commercialising the specific technology, but the licence may be narrower than the spinout’s intended commercial activities if the spinout agreement was not carefully drafted.
How background IP retained by the university creates FTO exposure: The most common spinout FTO gap involving background IP arises when the spinout’s commercial product incorporates technology that falls within the scope of background IP that the university retained rather than transferred. This can happen in several ways: the spinout’s product uses a core algorithm developed by the research group before the specific spinout-generating project; the product uses a material or formulation that was developed under a parallel research programme and is covered by a university patent that was not included in the spinout IP package; or the spinout’s manufacturing process incorporates a know-how element that is retained by the university as background IP. In each case, the spinout is commercialising technology that it does not have the right to commercialise without the university’s permission.
How to audit background IP before the first commercial deal: A background IP audit reviews the spinout agreement and the university’s IP register to identify all IP that the university retained that is relevant to the spinout’s current or planned commercial activities. For each retained IP right, the audit assesses whether the spinout’s commercial activities require a licence to that right and whether the existing spinout agreement provides one. Where gaps are identified — retained IP that the spinout uses or plans to use but does not have a licence for — the audit provides the basis for negotiating a licence-back or IP transfer from the university before the first commercial deal.
“The spinout that discovers a background IP gap at due diligence is in the worst possible negotiating position. The university knows the commercial deal is pending, the deal counterparty knows the gap has been identified, and the spinout needs a licence urgently. Discovering the gap 12 months earlier — through a systematic background IP audit — gives the spinout time to negotiate from a position that is not under deal-timeline pressure.”
Layer Two: Third-Party Tool Licences Embedded in the Research Phase
Research licences vs. commercial licences: Many of the software tools, databases, biological materials, and research reagents used in university R&D programmes are licensed under terms that explicitly restrict use to non-commercial research purposes. These research licences are standard practice: the licensor (typically a software company, data provider, or biological material supplier) grants access at preferential rates or free of charge for academic research, in exchange for a restriction on commercial use. When a spinout commercialises technology developed using these research-licensed tools, the commercial use of the resulting product may fall outside the permitted scope of the original research licence — requiring a separate commercial licence that has not been obtained.
The three most common categories of research-phase third-party IP:
Category 1: Research software licences Scientific computing software, simulation tools, analysis platforms, and development environments licensed under academic or research terms. MATLAB, certain bioinformatics tools, molecular modelling software, and specialised engineering simulation packages are commonly licensed to universities under research-only terms that do not permit commercial use of products developed using the software.
Category 2: Database and dataset access agreements Clinical data, genomic data, materials property databases, and proprietary datasets accessed under research data agreements that restrict commercial exploitation of findings derived from the data. Spinouts commercialising AI or data-driven technology developed using research-licensed datasets frequently need to review whether their training data access agreements permit commercial deployment of models trained on that data.
Category 3: Biological materials and research reagents Cell lines, antibodies, biological samples, and research reagents obtained under material transfer agreements (MTAs) that restrict commercial use of products developed using or incorporating the materials. For life science and biotech spinouts, the MTA stack from the research phase can be extensive and may include materials from multiple institutions with different commercial restriction terms.
How to identify and assess embedded research licences: A research licence audit reviews all third-party tool, data, and material agreements entered into during the research phase. For each agreement, the audit identifies: the scope of permitted use (research only, academic use, non-commercial); whether the commercial activities of the spinout fall within or outside this scope; and what the commercial licence terms are for tools or materials that require a separate commercial agreement. The audit output is a list of required commercial licences that the spinout needs to obtain before its commercial activities are legally clean.
Layer Three: The Technology Landscape That Was Never Cleared for FTO
Why R&D novelty assessment is not FTO: Academic research programmes assess novelty and inventive step for the purpose of patent filing and publication — to establish that the research generates genuinely new knowledge and is patentable where commercial value exists. This novelty assessment is not FTO. Novelty asks: is this new relative to the prior art? FTO asks: does this infringe any currently active third-party patent? The two questions can produce different answers for the same technology. A genuinely novel innovation can still infringe an active patent if a third party has independently claimed the same technical approach from a different angle, or if the spinout’s implementation of its novel innovation uses a method step that is covered by an existing patent on a different but overlapping technology.
How to scope a deep tech FTO when the technology is complex and novel: Deep tech technologies — quantum computing, advanced materials, synthetic biology, novel sensor systems — are often genuinely novel in the academic sense but sit in technology spaces that are also densely filed by large technology companies and industrial R&D programmes. The FTO scope for a deep tech spinout must cover both the primary technology classification for the spinout’s innovation and the adjacent technology classifications where large companies have filed patents covering different implementations of the same underlying technical principles. A quantum computing spinout’s FTO must cover both quantum algorithm patents and the classical computing and error correction patents that its implementation relies on. A synthetic biology spinout’s FTO must cover both the specific biological construct and the gene editing tool and vector delivery system patents that its laboratory protocol depends on.
Using the spinout’s own patent portfolio as an FTO input: Where the spinout has already filed patents covering its core technology, the patent filing process will have generated a prior art search that is a useful starting point for the FTO scope. The patents cited against the spinout’s applications by the patent examiner are the most relevant prior art in the technology space — and where the spinout has been granted patents over cited prior art, the examiner’s citation list reveals the blocking IP that was considered and distinguished. For spinouts with an active patent portfolio, the prosecution history of their own patents is one of the most efficient starting points for FTO scope identification.
How to Structure a Deep Tech Spinout FTO Before the First Commercial Deal
The complete deep tech spinout FTO has three parts that run in parallel. Our guide on when to conduct an FTO search sets out the general timing framework — and for deep tech spinouts, the timing recommendation to begin FTO well before the commercial deal timeline is even more important because the three-part analysis takes longer to complete than a standard startup FTO.
- Background IP audit. Review the spinout agreement and the university IP register to identify all retained IP relevant to current and planned commercial activities. Negotiate any required licence-backs or IP transfers before the commercial deal creates negotiating pressure. Document the outcome in a background IP clearance schedule that the deal counterparty can review at due diligence.
- Research licence audit. Review all third-party tool, data, and material agreements from the research phase. Identify all agreements with commercial use restrictions and assess whether the spinout’s commercial activities fall within or outside the permitted scope. Obtain required commercial licences before the commercial deal creates urgency. Document the commercial licence stack in a third-party IP clearance schedule.
- External patent landscape FTO. Conduct a full FTO analysis of the technology space covering the primary classification codes for the spinout’s technology and adjacent classifications where large company filings may cover overlapping technical approaches. Use the spinout’s own patent prosecution history as a scope input. Produce a formal FTO opinion that the deal counterparty can review and rely on at due diligence.
How Our FTO Service Covers Deep Tech Spinouts
Our freedom to operate service covers deep tech spinout FTO across all three layers: background IP audit in coordination with the spinout agreement and university IP register, research licence audit identifying commercial use restrictions in third-party agreements from the research phase, and external patent landscape FTO covering primary and adjacent technology classifications with prosecution history-informed scope. For spinouts approaching their first commercial deal, licence agreement, or Series A investor due diligence, we structure the three-part FTO to deliver all three clearance schedules on a coordinated timeline that meets the commercial deal requirements without cutting analytical corners in any of the three layers.
Deep tech spinout FTO has three layers: background IP from the founding university, research-phase third-party licences, and the external patent landscape. Our service covers all three — giving you a complete IP clearance position before your first commercial deal. → Contact Us
Conclusion: The Takeaway
Deep tech spinout FTO is a three-layer analysis that standard startup FTO does not cover. Background IP retained by the founding university, research-phase third-party licences with commercial use restrictions, and the external patent landscape that was never assessed for FTO clearance during the R&D phase — all three must be systematically reviewed before the first commercial deal creates the commercial and legal pressure that makes gap discovery most costly.
The spinout that completes all three layers before the deal timeline arrives is the one that reaches due diligence with a clean IP position and a documented clearance schedule rather than a gap that its deal counterparty discovers first. That preparation is the difference between a commercial deal that closes and one that stalls on IP — or closes on terms that reflect the IP uncertainty rather than the technology’s commercial value.
